PLYMOUTH MEETING, Pa. - INOVIO (NASDAQ: INO), a biotechnology company with a market capitalization of approximately $69 million, has announced positive results from a Phase 1/2 clinical trial of ...

Inovio (INO) announced that peer-reviewed data from its Phase 1/2 clinical trial with INO-3107 as a potential treatment for recurrent ...

PITTSBURGH (AP) — PITTSBURGH (AP) — The Kraft Heinz Company (KHC) on Wednesday reported fourth-quarter earnings of $2.13 billion. On a per-share basis, the Pittsburgh-based company said it had net ...

Precigen has a market cap of $468mn and a cash runway into 2026, but needs more funds for commercialization. Check out my ...

Poster will describe loss of detectable HPV-6 in Recurrent Respiratory Papillomatosis patients following treatment with INO-3107 American Association for Cancer Research – Immuno-Oncology Discovery ...

Precigen, Inc. (NASDAQ:PGEN), a biotechnology company specializing in gene and cell therapies with a market capitalization of $398.3 million, is on the cusp of a significant transformation as it ...

Recurrent respiratory papillomatosis (RRP) is a disease of the upper airway presenting with exophytic wart-like lesions. These lesions are considered benign with less than a 1–5% chance of malignant ...